array:19 [
  "pii" => "X0211699502027822"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:22-3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1766
    "formatos" => array:3 [
      "EPUB" => 173
      "HTML" => 1250
      "PDF" => 343
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027814"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:24-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2589
      "formatos" => array:3 [
        "EPUB" => 182
        "HTML" => 1931
        "PDF" => 476
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Inhibition of platelet aggregability by losartan in essential hypertension"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "24"
          "paginaFinal" => "28"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. PAVEL LEVY , C. YUNIS , J. OWEN , K. BRIDGET BROSNIHAN , R. SMITH , C. M. FERRARIO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. PAVEL LEVY , C. YUNIS , J. OWEN , K. BRIDGET BROSNIHAN , R. SMITH , C. M. FERRARIO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027814?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027814/v0_201502091327/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699502027830"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:20-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4049
      "formatos" => array:3 [
        "EPUB" => 192
        "HTML" => 3220
        "PDF" => 637
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Climaterio y riesgo cardiovascular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "20"
          "paginaFinal" => "21"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. ABELLÁN"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. ABELLÁN"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027830?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027830/v0_201502091327/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Kidney and aging"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "22"
        "paginaFinal" => "23"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "L. FERDER"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "L. FERDER"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Kidney and aging L. Ferder Universidad de Buenos Aires. Argentina. The progressive development of glomerulosclerosis is a well-known phenomenon that occurs in the aging kidney and in a variety of experimental models of renal injury. In the remnant kidney model, Brenner y cols., 1 had demonstrated that ACE inhibitos and angiotensin II antagonists can attenuate glomerulosclerosis. They also showed that both types of compound can lower intraglomerular pressure by altering the resistance of the efferent arteriole. Based on these findings they proposed that glomerular hypperfiltration is an underlying factor in the development of glomerulosclerosis. In a previous report we demonstrated that enalapril, administered to mice during 24 months, significantly decreased mesangial expansion, glomerulosclerosis and the loss of glomeruli normally associated to aging 2. In other models, the decrease of intraglomerular pressure by ACE inhibitors, as well as angiotensin II antagonists, accounts for the attenuation of glomerular injury 3. In addition to its protective actions on glomerular structure, chronic enalapril administration has been shown to decrease both peritubular and medullar interstitial sclerosis in aging mice 4, 5. In an attempt to further define the role of the reninangiotensin system in aging, we administered enalapril (10 mg/kg/day) and the angiotensin II receptor antagonist losartan (30 mg/kg/day) to Wistar rats since weaning. After 7 months of treatment, both of losartan and enalapril significantly decreased tubular atrophy and glomerular and interstitial fibrosis (table I). The protective effect of losartan and enalapril in the kidneys of the animals at 18 and 22 months was also analyzed. Reduced kidney damage was absolutely clear, losartan group presented lower glomerular and tubulointerstitial fibrosis, monocytic/macrophage infiltrates and tubular atrophy than control animals (F. Inserra, I. Stella, M. L. Kurnek, N. Terragno, N. Paglia, N. Basso, L. Ferder: losartan and enalapril protect gainst age related kidney lesions in normal rats treatd for 18 months of age [abstract]. 16th Scientific Meeting of the American Society of Hypertension, may 2001, San Francisco, USA). The difference found by electron microscopy in the cells of the proximal tubule at 18 months between control and losartan groups is outstanding, mainly related to higher brush border size and amount of mi- Table I. Kidney fibrosis. Effects of losartan and enalapril Control Interstitial fibrosis (%) Tubular atrophy (%) Collagen-III (%) -SM-actin (%) 1.39 1.22 1.17 0.89 ± ± ± ± 0.13 0.12 0.12 0.14 Enalapril 0.26 0.05 0.44 0.11 ± ± ± ± 0,8* 0.05* 0.10* 0.07* Losartán 0.39 0.16 0.80 0.39 ± ± ± ± 0.07* 0.08* 0.12* 0.14* These results were evaluated by a semiquantitative score 0-4. *p < 0.05 vs control. ANOVA Test. Table II. Losartan and enalapril protect against age related kidney lesions in normal rats treated from 12 to 18 months of age PGF Control Losartan Enalapril 2.71 ± 1.11 2.00 ± 0.29 0.83 ± 0.55 MM 2.71 ± 0.95 1.00 ± 0.41 0.58 ± 0.34 FS 1.64 ± 0.85 0.83 ± 0.37 0.08 ± 0.19 TD 2.36 ± 0.63 1.50 ± 0.82 0.60 ± 0.34 ICF 2.79 ± 0.39 2.08 ± 0.45 1.00 ± 0.50 IMF 1.93 ± 0.89 1.17 ± 0.24 0.10 ± 0.18 -A 1.29 ± 1.07 1.08 ± 0.67 0.40 ± 0.34 A score evaluation was applied&#59; lesions were considered as 0 = normal&#59; 1 = slight&#59; 2 = moderate and 3 = severe. *p < 0.05 vs C. PGF&#59; periglomerular fibrosis&#59; MM: mesangial matrix&#59; FS: focal sclerosis&#59; TD: tubular dilation&#59; ICF: interstitial cortical fibrosis&#59; IMF: interstitial medullar fibrosis&#59; -A: -SM-Actin. In summary, losartan and enalapril treatment from 12 to 18 months of age preserve renal function and structure from changes due to aging in the normal rat. 22 KIDNEY AND AGING tochondria in losartan treated animals as well as conservation of mitochondrial ultra structure and function, similar to younger animals. Finally, we were interested to find out if this protective effect should be produced if the treatment would have been started in older animals. Because of that, we repeat the experiments but in this opportunity the treatment was started at 12 months of age of the animals and the results were evaluated at 18 months. The results can be seen in table II (F. Inserra, I. Stella, M. L. Kurnek, N. Terragno, N. Paglia, N. Basso, L. Ferder: losartan and enalapril protect against age related kidney lesions in normal rats treated from 12 to 18 months of age [abstract]. J Am Soc Nephrol 12&#59; 679A, 2001). These data suggest that the renin-angiotensin system plays a role in the natural aging of the kidney. REFERENCES 1. Hostetter TH, Olson JL, Renneke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephron. A potentially adverse response to renal ablation. Am J Phisiol 241: F85-F93, 1981. 2. Ferder L, Inserra F, Romano L, Ercole L, Pszenny V: Decreased glomerulosclerosis in aging by angiotensin-converting anzyme inhibitors. J Am Soc Nephrol 5: 1147-1152, 1994. 3. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985. 4. Ferder LF, Inserra F, Romano L, Ercole L, Pszenny V: Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am J Physiol 256 (Cell Physiol) 34: C15-C18, 1993. 5. Inserra F, Romano L, Cavanagh EMV de, Ercole L, Ferder L, Gómez R: Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. J Am Soc Nephrol 7: 676-680, 1996. 23 "
    "pdfFichero" => "P7-E193-S140-A3686.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027822/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027822/v0_201502091327/en/P7-E193-S140-A3686.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027822?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Kidney and aging
L. FERDER
Leído
4918
Veces
se ha leído el artículo
1927
Total PDF
2991
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699502027822"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2002-04-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2002;22 Supl 2:22-3"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 1766
    "formatos" => array:3 [
      "EPUB" => 173
      "HTML" => 1250
      "PDF" => 343
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699502027814"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:24-8"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2589
      "formatos" => array:3 [
        "EPUB" => 182
        "HTML" => 1931
        "PDF" => 476
      ]
    ]
    "en" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Inhibition of platelet aggregability by losartan in essential hypertension"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "24"
          "paginaFinal" => "28"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. PAVEL LEVY , C. YUNIS , J. OWEN , K. BRIDGET BROSNIHAN , R. SMITH , C. M. FERRARIO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. PAVEL LEVY , C. YUNIS , J. OWEN , K. BRIDGET BROSNIHAN , R. SMITH , C. M. FERRARIO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027814?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027814/v0_201502091327/en/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699502027830"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2002-04-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2002;22 Supl 2:20-1"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 4049
      "formatos" => array:3 [
        "EPUB" => 192
        "HTML" => 3220
        "PDF" => 637
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Climaterio y riesgo cardiovascular"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "20"
          "paginaFinal" => "21"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "J. ABELLÁN"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "J. ABELLÁN"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027830?idApp=UINPBA000064"
    "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027830/v0_201502091327/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Kidney and aging"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "22"
        "paginaFinal" => "23"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "L. FERDER"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "L. FERDER"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XXII. Suplemento 2. 2002 Kidney and aging L. Ferder Universidad de Buenos Aires. Argentina. The progressive development of glomerulosclerosis is a well-known phenomenon that occurs in the aging kidney and in a variety of experimental models of renal injury. In the remnant kidney model, Brenner y cols., 1 had demonstrated that ACE inhibitos and angiotensin II antagonists can attenuate glomerulosclerosis. They also showed that both types of compound can lower intraglomerular pressure by altering the resistance of the efferent arteriole. Based on these findings they proposed that glomerular hypperfiltration is an underlying factor in the development of glomerulosclerosis. In a previous report we demonstrated that enalapril, administered to mice during 24 months, significantly decreased mesangial expansion, glomerulosclerosis and the loss of glomeruli normally associated to aging 2. In other models, the decrease of intraglomerular pressure by ACE inhibitors, as well as angiotensin II antagonists, accounts for the attenuation of glomerular injury 3. In addition to its protective actions on glomerular structure, chronic enalapril administration has been shown to decrease both peritubular and medullar interstitial sclerosis in aging mice 4, 5. In an attempt to further define the role of the reninangiotensin system in aging, we administered enalapril (10 mg/kg/day) and the angiotensin II receptor antagonist losartan (30 mg/kg/day) to Wistar rats since weaning. After 7 months of treatment, both of losartan and enalapril significantly decreased tubular atrophy and glomerular and interstitial fibrosis (table I). The protective effect of losartan and enalapril in the kidneys of the animals at 18 and 22 months was also analyzed. Reduced kidney damage was absolutely clear, losartan group presented lower glomerular and tubulointerstitial fibrosis, monocytic/macrophage infiltrates and tubular atrophy than control animals (F. Inserra, I. Stella, M. L. Kurnek, N. Terragno, N. Paglia, N. Basso, L. Ferder: losartan and enalapril protect gainst age related kidney lesions in normal rats treatd for 18 months of age [abstract]. 16th Scientific Meeting of the American Society of Hypertension, may 2001, San Francisco, USA). The difference found by electron microscopy in the cells of the proximal tubule at 18 months between control and losartan groups is outstanding, mainly related to higher brush border size and amount of mi- Table I. Kidney fibrosis. Effects of losartan and enalapril Control Interstitial fibrosis (%) Tubular atrophy (%) Collagen-III (%) -SM-actin (%) 1.39 1.22 1.17 0.89 ± ± ± ± 0.13 0.12 0.12 0.14 Enalapril 0.26 0.05 0.44 0.11 ± ± ± ± 0,8* 0.05* 0.10* 0.07* Losartán 0.39 0.16 0.80 0.39 ± ± ± ± 0.07* 0.08* 0.12* 0.14* These results were evaluated by a semiquantitative score 0-4. *p < 0.05 vs control. ANOVA Test. Table II. Losartan and enalapril protect against age related kidney lesions in normal rats treated from 12 to 18 months of age PGF Control Losartan Enalapril 2.71 ± 1.11 2.00 ± 0.29 0.83 ± 0.55 MM 2.71 ± 0.95 1.00 ± 0.41 0.58 ± 0.34 FS 1.64 ± 0.85 0.83 ± 0.37 0.08 ± 0.19 TD 2.36 ± 0.63 1.50 ± 0.82 0.60 ± 0.34 ICF 2.79 ± 0.39 2.08 ± 0.45 1.00 ± 0.50 IMF 1.93 ± 0.89 1.17 ± 0.24 0.10 ± 0.18 -A 1.29 ± 1.07 1.08 ± 0.67 0.40 ± 0.34 A score evaluation was applied&#59; lesions were considered as 0 = normal&#59; 1 = slight&#59; 2 = moderate and 3 = severe. *p < 0.05 vs C. PGF&#59; periglomerular fibrosis&#59; MM: mesangial matrix&#59; FS: focal sclerosis&#59; TD: tubular dilation&#59; ICF: interstitial cortical fibrosis&#59; IMF: interstitial medullar fibrosis&#59; -A: -SM-Actin. In summary, losartan and enalapril treatment from 12 to 18 months of age preserve renal function and structure from changes due to aging in the normal rat. 22 KIDNEY AND AGING tochondria in losartan treated animals as well as conservation of mitochondrial ultra structure and function, similar to younger animals. Finally, we were interested to find out if this protective effect should be produced if the treatment would have been started in older animals. Because of that, we repeat the experiments but in this opportunity the treatment was started at 12 months of age of the animals and the results were evaluated at 18 months. The results can be seen in table II (F. Inserra, I. Stella, M. L. Kurnek, N. Terragno, N. Paglia, N. Basso, L. Ferder: losartan and enalapril protect against age related kidney lesions in normal rats treated from 12 to 18 months of age [abstract]. J Am Soc Nephrol 12&#59; 679A, 2001). These data suggest that the renin-angiotensin system plays a role in the natural aging of the kidney. REFERENCES 1. Hostetter TH, Olson JL, Renneke HG, Venkatachalam MA, Brenner BM: Hyperfiltration in remnant nephron. A potentially adverse response to renal ablation. Am J Phisiol 241: F85-F93, 1981. 2. Ferder L, Inserra F, Romano L, Ercole L, Pszenny V: Decreased glomerulosclerosis in aging by angiotensin-converting anzyme inhibitors. J Am Soc Nephrol 5: 1147-1152, 1994. 3. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619, 1985. 4. Ferder LF, Inserra F, Romano L, Ercole L, Pszenny V: Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am J Physiol 256 (Cell Physiol) 34: C15-C18, 1993. 5. Inserra F, Romano L, Cavanagh EMV de, Ercole L, Ferder L, Gómez R: Renal interstitial sclerosis in aging: effects of enalapril and nifedipine. J Am Soc Nephrol 7: 676-680, 1996. 23 "
    "pdfFichero" => "P7-E193-S140-A3686.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000022000000S2/v0_201502091327/X0211699502027822/v0_201502091327/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000022000000S2/v0_201502091327/X0211699502027822/v0_201502091327/en/P7-E193-S140-A3686.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699502027822?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 9 10 19
2024 Octubre 43 45 88
2024 Septiembre 35 24 59
2024 Agosto 53 62 115
2024 Julio 37 38 75
2024 Junio 32 33 65
2024 Mayo 47 30 77
2024 Abril 29 30 59
2024 Marzo 26 23 49
2024 Febrero 38 35 73
2024 Enero 34 30 64
2023 Diciembre 38 19 57
2023 Noviembre 29 26 55
2023 Octubre 23 27 50
2023 Septiembre 18 28 46
2023 Agosto 26 13 39
2023 Julio 29 23 52
2023 Junio 27 24 51
2023 Mayo 34 34 68
2023 Abril 16 25 41
2023 Marzo 15 21 36
2023 Febrero 17 20 37
2023 Enero 24 27 51
2022 Diciembre 25 32 57
2022 Noviembre 31 19 50
2022 Octubre 26 44 70
2022 Septiembre 35 26 61
2022 Agosto 25 42 67
2022 Julio 29 40 69
2022 Junio 21 21 42
2022 Mayo 20 46 66
2022 Abril 28 40 68
2022 Marzo 26 40 66
2022 Febrero 27 28 55
2022 Enero 41 44 85
2021 Diciembre 16 44 60
2021 Noviembre 25 31 56
2021 Octubre 28 48 76
2021 Septiembre 37 34 71
2021 Agosto 24 34 58
2021 Julio 48 40 88
2021 Junio 26 23 49
2021 Mayo 49 27 76
2021 Abril 72 30 102
2021 Marzo 68 28 96
2021 Febrero 40 22 62
2021 Enero 22 17 39
2020 Diciembre 24 12 36
2020 Noviembre 19 8 27
2020 Octubre 13 17 30
2020 Septiembre 15 10 25
2020 Agosto 24 11 35
2020 Julio 39 11 50
2020 Junio 34 20 54
2020 Mayo 38 13 51
2020 Abril 27 16 43
2020 Marzo 23 12 35
2020 Febrero 30 16 46
2020 Enero 44 26 70
2019 Diciembre 24 14 38
2019 Noviembre 21 12 33
2019 Octubre 13 6 19
2019 Septiembre 15 9 24
2019 Agosto 4 12 16
2019 Julio 19 11 30
2019 Junio 14 5 19
2019 Mayo 9 18 27
2019 Abril 40 17 57
2019 Marzo 19 14 33
2019 Febrero 5 7 12
2019 Enero 18 12 30
2018 Diciembre 18 19 37
2018 Noviembre 19 10 29
2018 Octubre 22 8 30
2018 Septiembre 23 4 27
2018 Agosto 11 10 21
2018 Julio 14 5 19
2018 Junio 17 11 28
2018 Mayo 17 9 26
2018 Abril 10 1 11
2018 Marzo 11 7 18
2018 Febrero 6 1 7
2018 Enero 12 4 16
2017 Diciembre 19 6 25
2017 Noviembre 6 2 8
2017 Octubre 15 5 20
2017 Septiembre 8 2 10
2017 Agosto 16 5 21
2017 Julio 12 5 17
2017 Junio 17 5 22
2017 Mayo 19 4 23
2017 Abril 12 1 13
2017 Marzo 9 7 16
2017 Febrero 5 2 7
2017 Enero 17 2 19
2016 Diciembre 15 6 21
2016 Noviembre 22 16 38
2016 Octubre 25 6 31
2016 Septiembre 42 1 43
2016 Agosto 50 2 52
2016 Julio 73 5 78
2016 Junio 65 0 65
2016 Mayo 68 0 68
2016 Abril 32 0 32
2016 Marzo 36 0 36
2016 Febrero 45 0 45
2016 Enero 17 0 17
2015 Diciembre 26 0 26
2015 Noviembre 32 0 32
2015 Octubre 23 0 23
2015 Septiembre 22 0 22
2015 Agosto 22 0 22
2015 Julio 23 0 23
2015 Junio 6 0 6
2015 Mayo 13 0 13
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?